1. Annual Report 2025
  2. Research
  3. RWEpi

RWEpi

Real World Epidemiology Research Group

RWEpi is a multidisciplinary team that includes epidemiologists, statisticians, health professionals, data scientists and pre- and post-doctoral researchers with extensive experience in the analysis and interpretation of real-world data.

The main objective is to generate reliable scientific evidence by using routinely collected data from different health system settings.

The group participates in national and international studies focused on understanding the natural history and determinants of multiple diseases, the safety and efficacy of new drugs and vaccines, and the implementation of methods to analyze and evaluate the quality of real-world data.

It also develops research in the pediatric population and pregnant women, with the creation of a large cohort linked to the electronic medical record of the primary care of Catalonia of mothers and children as well as on health inequalities and the role of lifestyle and environmental exposures on health.

Group projects

  • Utilization and safety of antidementia treatments: a large longitudinal population-based study in Catalonia. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2022-2025. IP: Carlen Reyes Reyes.

  • Time trends in prevalence, incideTime trends in prevalence, incidence and survival of cancer in the OHDSI Networknce and survival of cancer. 2024-2026. IP: Talita Duarte Salles.

  • Time trends in incidence and prevalence of sexually transmitted infections among migrants in Catalonia: an analysis of primary healthcare records. 2025-2027. IP: Talita Duarte Salles.

  • Time trends and socioeconomic factors associated with cancer incidence for five solid tumour sites in Catalonia from 2009 to 2018. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2022-2025. IP: Talita Duarte Salles.

  • Temporal trends of mental disorders from 2006 to 2024 using large real-world data. 2024-2025. IP: Andrea Pistillo.

  • Study of exposure and use patterns of alternatives to ranitidine-containing medicines in patients treated with ranitidine. IQVIA Solutions BV. 2022-2025. IP: Talita Duarte Salles.

  • Social inequalities in eating disorders. Agència de Salut Pública de Barcelona (ASPB). 2025-2027. IP: Talita Duarte Salles.

  • Short term effects of temperature and air pollution on health in Barcelona and its metropolitan area considering sociodemographic and geographical inequalities. 2023-2026. IP: Andrea Pistillo.

  • Real-world coverage and effectiveness of COVID-19 vaccines in vulnerable populations living in Catalonia. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2023-2026. IP: Talita Duarte Salles.

  • Proyecto validación Lantitaps. 2022-2025. IP: Diana Puente Baliarda.

  • Neurodegeneration Research Programme towards better understanding of Phenotyping, Treatment Patterns, and Health Care Resource Use in Cluster Headache (CH) in Europe. EHDEN Foundation. 2024-2026. IP: Talita Duarte Salles.

  • Maternal Urban Exposures, Socioeconomic Context, and Birth Outcomes: A Population Based Longitudinal Study in Catalonia, Spain. 2023-2026. IP: Alicia Abellan Ecija.

  • Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus. University of California, Los Angeles campus (UCLA). 2022-2025. IP: Talita Duarte Salles.

  • Iimplementación de una prueba diagnóstica para incrementar la eficacia desde atención primaria en la identificación de pacientes con hipolactasia o deficiencia en lactasa intestinal. EAP Sardenya. 2025-2028. IP: Carlen Reyes Reyes.

  • European Non-interventional Post Authorization Safety Study for romosozumab by the EU-ADR Alliance. 2018-2026. IP: Carlen Reyes Reyes.

  • Epidemiology and burden of imminent subsequent fractures in postmenopausal women. University of Oxford. 2023-2026. IP: Carlen Reyes Reyes.

  • Encuesta sobre preferencias de medicación entre pacientes con y en riesgo de enfermedad cardiovascular aterosclerótica (ECVA) en la UE5. Merck Sharp & Dohme de España, S.A.; Oracle Ibérica, S.R.L. 2025-2028. IP: Carlen Reyes Reyes.

  • Effects of Angiotensin-converting enzyme Inhibitors and Angiotensin receptor blockers: protocol for a Spanish cohort study using routinely collected electronic health records with validation against the ONTARGET trial. London School of Hygiene & Tropical Medicine. 2022-2025. IP: Carlen Reyes Reyes.

  • Disseny i validació d'un sistema basat en ia-generativa per al suport a l'assistant clínic a l'atenció primària. EAP Sardenya. 2025-2028. IP: Carlen Reyes Reyes.

  • Development of new growth curves for children and adolescents in Catalonia. 2023-2026. IP: Talita Duarte Salles.

  • Determinants associated with non-vaccination against influenza in pregnant women in Barcelona: a qualitative explorative descriptive study. 2024-2027. IP: Elena Roel Herranz.

  • Designing and validating a Real-time Adverse Drug reaction Automated Recognition tool for primary care: the RADAR study. Agència de Gestió d'Ajuts Univ i de Recerca (AGAUR). 2024-2027. IP: Carlen Reyes Reyes.

  • DARWIN EU® - Treatment patterns of drugs used in adult and paediatric population with systemic lupus erythematosus. Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2023-2025. IP: Talita Duarte Salles.

  • DARWIN EU® - Suicidality following exposure to doxycycline. Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2024-2025. IP: Talita Duarte Salles.

  • DARWIN EU® - Monitoring prescription of medicines for public health emergencies at risk of shortages. Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2023-2025. IP: Talita Duarte Salles.

  • DARWIN EU® - EHDS Use Case: Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV-2 in the context of the OMICRON variant. Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2023-2025. IP: Talita Duarte Salles.

  • DARWIN EU® - Effectiveness of COVID-19 vaccines on severe COVID-19 and post-acute outcomes of SARS-CoV-2 infection. Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2024-2026. IP: Talita Duarte Salles.

  • DARWIN EU® - DUS in patients with major depressive disorder. Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2023-2025. IP: Talita Duarte Salles.

  • DARWIN EU® - Comparing direct and indirect methods to estimate prevalence of chronic diseases using real-world data. Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2024-2025. IP: Talita Duarte Salles.

  • DARWIN EU® - Age-specific incidence rates of RSV-related disease in Europe. Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2024-2025. IP: Talita Duarte Salles.

  • DARWIN EU® - Incidence of suicidality in patients with specific chronic skin conditions. Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2024-2027. IP: Talita Duarte Salles.

  • Characterisation and risks of long-term COVID-19 outcomes using large real world data. Instituto de Salud Carlos III. 2022-2025. IP: Talita Duarte Salles.

  • Air pollution in relation to COVID-19 morbidity and mortality: a large population-based cohort study in Catalonia, Spain (COVAIR-CAT). Fundación Privada Instituto de Salud Global Barcelona (ISGlobal). 2022-2025. IP: Talita Duarte Salles.

  • Adiposidad durante la vida y riesgo y mortalidad de cáncer: el rol de comorbilidades e intervenciones para pérdida de peso. (PI23/01186). Instituto de Salud Carlos III. 2024-2026. IP: Talita Duarte Salles.

  • A Randomized, Double-Blind, Controlled Trial to Evaluate the Efficacy and Safety of a Combination of Xyloglucan and Gelose in the treatment of acute diarrhea in adults. (XILAPLUS AF). Noventure, S.L. 2025IP: Carlen Reyes Reyes.

  • Statins use and portal vein thrombosis in patients with cirrhosis in a Primary Care Setting in Catalonia from 2010 to 2023. 2025-2026. IP: Talita Duarte Salles.

  • Post-authorisation safety study to evaluate the utilisation and safety of atogepant in patients with migraine and significant cardiovascular and/or cerebrovascular disease in European countries. Abbvie INC; European Medicines Agency (EMA); Pharmo Institute N.V. 2025-2026. IP: Talita Duarte Salles.

  • Phenotyping and Treatment Patterns in Cluster Headache in Europe: A Multinational, Multidatabase Network Study. Stichting European Health and Data Evidence Network. 2025-2026. IP: Talita Duarte Salles.

  • Incidencia y asociación entre la exposición a las medicaciones potencialmente inapropiadas de la herramienta STOPPFall y el riesgo de eventos adversos: estudio de cohortes de base poblacional. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2024-2027. IP: Carlen Reyes Reyes.

  • Incidence, prevalence, and characterisation of medicines with suggested drug shortages in Europe. 2024-2026. IP: Talita Duarte Salles.

  • Drug Utilization Study Evaluating Additional Risk Minimization Measures for Upadacitinib in the Treatment of Atopic Dermatitis in Europe. AbbVie Inc. 2024-2027. IP: Talita Duarte Salles.

  • DARWIN EU® -Characterisation of acute renal outcomes and severe diabetic complications during the use of metformin and iodinated contrast agents. Agencia Europea de Medicamentos (EMA); Erasmus Universitair Medisch Centrum Rotterdam (ERASMUS MC). 2025-2026. IP: Elena Roel Herranz.

  • DARWIN EU® - Uptake of meningococcal vaccines by the target population in Europe. Agencia Europea de Medicamentos (EMA); Erasmus Universitair Medisch Centrum Rotterdam (ERASMUS MC). 2025-2026. IP: Elena Roel Herranz.

  • DARWIN EU® - Trends in utilisation of Attention-Deficit Hyperactivity Disorder (ADHD) Medications (P3 C1-004). Erasmus Universitair Medisch Centrum Rotterdam (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.

  • DARWIN EU® - Frailty and polypharmacy among adults aged 18 and above with cancer at the time of diagnosis. Erasmus Universitair Medisch Centrum Rotterdam (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.

  • DARWIN EU® - Effectiveness of Human Papillomavirus Vaccines (HPV) to prevent cervical cancer. Erasmus Universitair Medisch Centrum Rotterdam (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.

  • DARWIN EU® - Drug Utilisation Study on Antibiotics in the 'Access' category of the WHO AWaRe classification of antibiotics for evaluation and monitoring of use. Erasmus Universitair Medisch Centrum Rotterdam (EMC); European Medicines Agency (EMA). 2025-2026. IP: Elena Roel Herranz.

  • DARWIN EU® - Drug utilisation of salbutamol products for inhalation and therapeutic alternative inhalation products. Erasmus Universitair Medisch Centrum Rotterdam (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.

  • DARWIN EU® - Characterising STOPP criteria medication use in people with recurrent falls. Erasmus Universitair Medisch Centrum Rotterdam (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.

  • DARWIN EU® - Background incidence rates of selected vaccine adverse events of special interest (AESIs) in Europe. Erasmus Universitair Medisch Centrum Rotterdam (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.

  • DARWIN EU® - Azathioprine - user characteristics. Erasmus Universitair Medisch Centrum Rotterdam (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.

  • DARWIN EU® - Antipsychotic prescribing in people with dementia in Europe: a descriptive analysis of trends and patient characteristics. Erasmus Universitair Medisch Centrum Rotterdam (EMC); European Medicines Agency (EMA). 2024-2027. IP: Talita Duarte Salles.

  • DARWIN EU® - Antipsychotic prescribing in Europe: a descriptive analysis of trends and patient characteristics. European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.

  • DARWIN EU® - Antipsychotic prescribing in children in Europe: a descriptive analysis of trends and patient characteristics. Agencia Europea de Medicamentos (EMA); Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2025-2026. IP: Elena Roel Herranz.

  • DARWIN - Clozapine and the incidence of agranulocytosis over time (P4-C1-001). Erasmus Universitair Medisch Centrum Rotterdam (EMC); European Medicines Agency (EMA). 2025-2026. IP: Elena Roel Herranz.

  • Characterization of incidental and chronic use of macrolides in patients with asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap syndrome (ACOS); a pharmacoepidemiologic drug utilization study with data mapped to the Observational Medical Outcomes Partnership.

  • Common Data Model (OMOP-CDM). Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2024-2027. IP: Talita Duarte Salles.

  • Asociación entre los niveles de vitamina D en sangre, los suplementos con vitamina D y las fracturas osteoporóticas en la población catalana: estudio de base poblacional. 2024-2027. IP: Carlen Reyes Reyes.

Group publications

  • Xie JQ, Du MK, Guo YC, Barboza C, Brash JT, Delmestri A et al. Trends in prescription opioid use in Europe: A DARWIN EU® multinational cohort study including seven European countries. Front. Pharmacol. 2025;161608051-1608051. PMID:40900825.

  • Cuyàs B, Alvarado Tapias E, Tan EH, Golozar A, Duarte Salles T, Delmestri A et al. Trends in incidence, prevalence, and survival of primary liver cancer in the United Kingdom (2000-2021). Eur. J. Public Health. 2025;36(2):PMID:41212072.

  • Lopez Jimenez T, Plana Ripoll O, Duarte Salles T, Palomar Cros A, Puente D. The effect between metabolic syndrome and life expectancy after cancer diagnosis: Catalan cohort study. BMC Public Health. 2025;25(1):178-178. PMID:39825260.

  • Bellas L, Català M, Burn E, Guo YC, Du M, Verhamme K et al. Secular Trends in the Use of Valproate-Containing Medicines in Women of Childbearing Age in Europe: A Multinational DARWIN EU Network Study. Pharmacoepidemiol. Drug Saf. 2025;34(10):PMID:41099219.

  • Bennett M, López Jiménez T, Medina Perucha L, León Gómez BB, Berenguera A, Jacques Aviñó C. Risk perception and coping mechanisms by gender identity and education level during the COVID-19 syndemic in Spain. BMC Psychol. 2025;13(1):598-598. PMID:40462188.

  • Morales DR, Bu F, Viernes B, DuVall SL, Matheny ME, Simon KR et al. Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study. Diabetes Care. 2025;48(8):1386-1394. PMID:40465422.

  • Pera V, Lepouttre H, Barboza C, Palomar Cros A, López Sánchez I, Duarte Salles T et al. Macrolide prescribing and preemptive electrocardiograms in asthma, COPD, ACO, and general population: a drug-utilization study. J. Asthma. 2026;63(2):1-14. PMID:41250618.

  • Aragonès E, Lozano Sánchez A, López Jiménez T, Bennett M, Evangelidou S, Francisco E et al. Incidence trends and clinical management of self-harm in adolescents and young adults in catalonia: primary care cohort study (2013-2022). Eur. Child Adolesc. Psych. 2025;35(2):437-448. PMID:40884581.

  • Pedregal Pascual P, Guarner Argente C, Tan EH, Golozar A, Duarte Salles T, Rosen AW et al. Incidence and survival of colorectal cancer in the United Kingdom from 2000-2021: a population-based cohort study. Am. J. Gastroenterol. 2025;120(12):2909-2917. PMID:40167184.

  • Pistillo A, Giuliodori A, Palomar Cros A, Gallo E, Aragonés E, Ballester J et al. High temperature and mental health in 3.3 million adults living in Barcelona metropolitan area: a 12-year time series analysis of primary care data. Environ. Int. 2025;203109748-109748. PMID:40886399.

  • Abellan A, Burn E, Trinh NTH, Burkard T, Callahan A, Fernández Bertolín S et al. Expanding the OMOP Common Data Model to Support Perinatal Research in Network Studies. Pharmacoepidemiol. Drug Saf. 2025;34(2):PMID:39950235.

  • Roel E, Henderson E, Valmayor S, Porthé V, Asensio A, Ramírez Morros A et al. Effectiveness of CONFIVAC, an intervention to enhance paediatric nurses and paediatricians skills to promote vaccination: A mixed-methods cluster randomized trial. Vaccine. 2025;62127603-127603. PMID:40818260.

  • López Güell K, Català M, Dedman D, Duarte Salles T, Kolde R, López Blasco R et al. Clusters of post-acute COVID-19 symptoms: a latent class analysis across 9 databases and 7 countries. J. Clin. Epidemiol. 2025;185111867-111867. PMID:40517846.

  • Pineda Moncusí M, Rekkas A, Martínez Pérez Á, Leis A, Lopez Gomez C, Fey E et al. Changes in use and utilisation patterns of drugs with reported shortages between 2010 and 2024 in Europe and North America: a network cohort study. Lancet Public Health. 2025;10(10): PMID:40992879.

  • Gallardo Nuell L, Blanch J, Leal Y, Coral DE, Duarte Salles T, Giordano GN et al. BMI-residualized data uncovers a cluster of people with type 2 diabetes and increased serum ferritin protected from cardiovascular disease. Cardiovasc. Diabetol. 2025;24(1):139-139. PMID:40140920.

  • Reyes C, Pou MA, Diaz Torne C, Carbonell Abella C, Brotons C, Martinez Laguna D. Association of morphine vs. fentanyl prescription dispensation with adverse clinical outcomes. Front. Pharmacol. 2025;161579634-1579634. PMID:40635750.

  • Henderson E, Valmayor S, Porthé V, Asensio A, Bruna X, Elizondo Alzola U et al. A mixed methods study protocol for CONFIVAC, an intervention to enhance paediatric nurses' and paediatricians' skills to promote vaccination and vaccine confidence. Vaccine: X. 2025;24.

  • Sánchez IL, Palomar Cros A, Giuliodori A, Granés L, Roel E, Duarte Salles T. Trends in incidence of primary colorectal cancer in Catalonia, Spain, from 2007 to 2023: A population-based cohort study. Ann. Oncol. 2025;36.

  • Pou MA, Reyes C, Martinez Laguna D, Satorra P, Tebe C, Dalbeth N et al. The young, the metabolic andthe hypertensive. A cluster analysis of gout characteristics and comorbidities. Ann. Rheum. Dis. 2025;841585-1586.

  • Bennett M, Lozano A, Evangelidou S, Guzmán Molina C, Romaní O, Jacques Aviñó C. Qualitative study of structural inequalities in the emotional well-being of adolescents and their families in catalonia. Gac. Sanit. 2025;39.

  • Amini M, Black A, van Leeuwen GJ, Duarte Salles T, Palomar Cros A, Giuliodori A et al. Incidence Rates of Suicidality Related Events in Patients with Specific Chronic Skin Conditions. Pharmacoepidemiol. Drug Saf. 2025;34227-227.

  • Pou MA, Reyes C, Martinez Laguna D, Tebe C, Satorra P, Dalbeth N et al. Gout characteristics, comorbidities and management in a long primary care database from catalonia: the gotap study. Ann. Rheum. Dis. 2025;841582-1583.

  • Bennett M, López Jiménez T, Lozano Sánchez A, Aragonès E, Jacques Aviñó C. Factors associated with anxiety and depression in adolescents and young adults in catalonia from 2008 to 2022: an intersectional analysis. Gac. Sanit. 2025;39.

  • Granés L, Pistillo A, Palomar A, Espiell A, Gallo E, Ballester J et al. Exposure to high temperatures and inequalities in the risk of gestational diabetes: a time-series study in an urban setting. Gac. Sanit. 2025;39.

  • Valmayor S, Roel E, Gabarró S, Gil S, Salobral R. Evaluation of the sexual and reproductive health program, sirian, with a population in a situation of high social vulnerability. Gac. Sanit. 2025;39.

  • Lozano Sánchez A, Martínez Hernáez A, Bennett M, Guzmán Molina C, Jacques Aviñó C. Emotional distress in adolescents according to health professionals: a qualitative study and critical approach. Gac. Sanit. 2025;39

  • Raventós B, Mercadé Besora N, Trinh NTH, Hayati S, Burkard T, Burn E et al. Effectiveness of COVID-19 Mrna Primary Vaccination during Pregnancy: A Target Trial Emulation Study Using Data from 4 European Countries. Pharmacoepidemiol. Drug Saf. 2025;34419-419.

  • Mercadé Besora N, Raventós B, Trinh N, Li H, Hayati S, Giuliodori A et al. Effectiveness of covid-19 mrna primary and booster vaccination during pregnancy: a target trial emulation and meta-analysis of data from 4 european countries. Gac. Sanit. 2025;39.

  • Mercadé Besora N, Raventós B, Trinh NTH, Hayati S, Burkard T, Burn E et al. Effectiveness of Booster (Third-Dose) COVID-19 Vaccination during Pregnancy: A Target Trial Emulation Study Using 4 European Databases. Pharmacoepidemiol. Drug Saf. 2025;34632-632.

  • Li XT, Mercadé Besora N, Lam A, Barboza C, Delmestri A, Duarte Salles T et al. Effectiveness and Waning of the Fourth Dose Mrna COVID-19 Vaccines for the Prevention of Severe COVID-19 Related Outcomes. Pharmacoepidemiol. Drug Saf. 2025;34247-247.

  • Valmayor S, Roel E, Gil S, Gabaró S, Salobral R. Description of sexual and reproductive health in a population in a situation of high social vulnerability. Gac. Sanit. 2025;39416-416.

  • Palomar Cros A, Giuliodori A, López Sánchez I, Granés L, Roel E, Duarte Salles T. Data analysis and real-world interrogation network (DARWIN EU®): a successful example of sidiap use for regulatory purposes. Gac. Sanit. 2025;39.

  • Du M, Wang WN, Burn E, Duarte Salles T, Palomar Cros A, Giuliodori A et al. DARWIN-EU®-Antipsychotic Prescribing in People with Dementia in Europe: A Descriptive Analysis of Trends and Patient Characteristics. Pharmacoepidemiol. Drug Saf. 2025;34292-292.

  • Guo YC, Burn E, Duarte Salles T, Sánchez IL, Verhamme K, Barboza C et al. DARWIN EU®-Trends of Use of Glucagon-like Peptide-1 Receptor Agonists in Real-World Data from Five European Countries. Pharmacoepidemiol. Drug Saf. 2025;34293-294.

  • Politi J, Black A, Barboza C, Mosseveld M, Crespo LP, Palomar Cros A et al. DARWIN EU®-Prevalence of Frailty and Polypharmacy in Selected Cancers: results from Six European Countries in a Real-World Context. Pharmacoepidemiol. Drug Saf. 2025;34201-202.

  • Mendez A, Jadhav G, Cavlina M, Delmestri A, Duarte Salles T, Giuliodori A et al. DARWIN EU®-Prescription Pattern of STOPP Section K Criteria Medication in Elderly with and without Recurrent Falls. Pharmacoepidemiol. Drug Saf. 2025;34334-334.

  • Politi J, Inberg G, Niemen T, Wahlfors T, Brash J, Kaczmarczyk I et al. DARWIN EU®-Incidence of Erectile Dysfunction, Insomnia, and Hypertension in Incident Migraine and by Prophylactic Treatment initiation, Including CGRP Antagonists. Pharmacoepidemiol. Drug Saf. 2025;3469-69.

  • Mendez A, Jadhav G, Cavlina M, Delmestri A, Duarte Salles T, Giuliodori A et al. DARWIN EU®-Characterisation and Survival of Elderly with Recurrent Falls in Europe. Pharmacoepidemiol. Drug Saf. 2025;34232-232.

  • Li XT, Burn E, Prieto Alhambra D, Prats Uribe A, Delmestri A, Mosseveld M et al. DARWIN EU®-Background Incidence Rates of Selected Vaccine Adverse Events of Special Interest (Aesis) in Europe. Pharmacoepidemiol. Drug Saf. 2025;343-4.

  • Wang W, Du MK, Burn E, Salles TD, Palomar Cros A, Giuliodori A et al. DARWIN EU®-Antipsychotic Prescribing in the General Population in Europe: A Descriptive Analysis of Trends and Patient Characteristics. Pharmacoepidemiol. Drug Saf. 2025;3490-90.

  • Hunt N, van Leeuwen GJ, van Kessel M, Palomar Cros A, Delmestri A, Giuliodori A et al. DARWIN EU®-a Multi-National Network Cohort Study of the Effect of Doxycycline versus Active Comparators on the Risk of Suicidality in Individuals with Acne. Pharmacoepidemiol. Drug Saf. 2025;34589-590.

  • Saura Lazaro A, Alcalde Herraiz M, Burn E, Delmestri A, Omulo H, Claus M et al. Darwin EU® characterizing clinically recognized hypertrophic cardiomyopathy in six european countries: a descriptive analysis using real-world data. Value Health. 2025;28(12).

  • Politi J, Inberg G, Nika I, Delmestri A, Jadhav G, Mendez A et al. DARWIN EU ® -Incidence of Myoclonus in Heart Failure: A Descriptive Analysis in Patients Treated with Sacubitril/ Valsartan and Other Treatments. Pharmacoepidemiol. Drug Saf. 2025;34495-496.

  • López Sánchez I, Giuliodori A, Palomar Cros A, Roel E, Duarte Salles T, Granés L. Characterising cancer patients in catalonia using real-world data from sidiap: insights across 34 cancer types. Gac. Sanit. 2025;39.

  • Pistillo A, Giuliodori A, Palomar Cros A, Petricola S, Guxens M, Duarte Salles T. Air pollution and mental health in barcelona: a time series analysis of 12 years of primary care data. Gac. Sanit. 2025;39.

  • Jacques Aviñó C, Lozano A, Malgosa E, Bennett M, Guzmán Molina C, Evangelidou S et al. Adolescence, emotional health, and inequalities in catalonia: a photovoice study. Gac. Sanit. 2025;39.

Anar a l'inici